OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6849$1431.0055

Nihon Kohden Corp

Advanced Medical Equipment & TechnologyVerified

Nihon Kohden Corp maintains a strong liquidity position with a current ratio of 2.53 and a price-to-book ratio of 1.27, indicating a conservative capital structure and low leverage. The company's cash and equivalents amount to ¥28.43 billion, and its long-term debt is relatively modest at ¥26.08 billion, resulting in a debt-to-equity ratio of 0.15. This liquidity profile supports operational flexibility and resilience against short-term financial shocks. Profitability metrics show that Nihon Kohden Corp generates a return on equity (ROE) of 7.85% and a return on assets (ROA) of 5.46%. These figures are in line with the industry's preferred metrics for capital efficiency and asset utilization. The company's operating income of ¥19.82 billion and net income of ¥14.10 billion reflect a healthy margin structure, with a gross profit of ¥117.16 billion supporting its profitability. Geographically, Nihon Kohden Corp's revenue is primarily concentrated in Japan, with a significant portion of its business derived from domestic healthcare institutions. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulates it from foreign exchange volatility. Segment-wise, the company operates in a single primary business line focused on advanced medical equipment and technology. Looking ahead, Nihon Kohden Corp is projected to maintain a stable growth trajectory, with revenue expected to remain relatively flat in the current fiscal year and show modest growth in the following year. The company's capital expenditure of ¥8.71 billion reflects ongoing investment in production and R&D, supporting long-term innovation and product development. Risk factors for Nihon Kohden Corp include regulatory changes in the healthcare sector and potential supply chain disruptions. However, the company's low liquidity and dilution risk scores suggest that these risks are currently well-managed. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains robust. Recent events, including quarterly earnings reports and regulatory filings, indicate that Nihon Kohden Corp continues to operate within a stable financial and operational environment. The company has not disclosed any material changes in its business strategy or significant new risks in its recent filings.

30-day price · 6849-87.00 (-5.7%)
Low$1408.50High$1573.50Close$1443.00As of28 May, 00:00 UTC
Profile
CompanyNihon Kohden Corp
Ticker6849.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Nihon Kohden Corp is a Japanese manufacturer and distributor of advanced medical equipment and technology, including diagnostic imaging systems, patient monitoring devices, and clinical laboratory equipment.

Classification. Nihon Kohden Corp is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

Nihon Kohden Corp maintains a strong liquidity position with a current ratio of 2.53 and a price-to-book ratio of 1.27, indicating a conservative capital structure and low leverage. The company's cash and equivalents amount to ¥28.43 billion, and its long-term debt is relatively modest at ¥26.08 billion, resulting in a debt-to-equity ratio of 0.15. This liquidity profile supports operational flexibility and resilience against short-term financial shocks. Profitability metrics show that Nihon Kohden Corp generates a return on equity (ROE) of 7.85% and a return on assets (ROA) of 5.46%. These figures are in line with the industry's preferred metrics for capital efficiency and asset utilization. The company's operating income of ¥19.82 billion and net income of ¥14.10 billion reflect a healthy margin structure, with a gross profit of ¥117.16 billion supporting its profitability. Geographically, Nihon Kohden Corp's revenue is primarily concentrated in Japan, with a significant portion of its business derived from domestic healthcare institutions. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulates it from foreign exchange volatility. Segment-wise, the company operates in a single primary business line focused on advanced medical equipment and technology. Looking ahead, Nihon Kohden Corp is projected to maintain a stable growth trajectory, with revenue expected to remain relatively flat in the current fiscal year and show modest growth in the following year. The company's capital expenditure of ¥8.71 billion reflects ongoing investment in production and R&D, supporting long-term innovation and product development. Risk factors for Nihon Kohden Corp include regulatory changes in the healthcare sector and potential supply chain disruptions. However, the company's low liquidity and dilution risk scores suggest that these risks are currently well-managed. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains robust. Recent events, including quarterly earnings reports and regulatory filings, indicate that Nihon Kohden Corp continues to operate within a stable financial and operational environment. The company has not disclosed any material changes in its business strategy or significant new risks in its recent filings.
Key takeaways
  • Nihon Kohden Corp maintains a conservative capital structure with strong liquidity and low leverage.
  • The company's profitability metrics are in line with industry standards, reflecting efficient operations.
  • Revenue is primarily concentrated in Japan, with limited international diversification.
  • The company is projected to maintain stable growth with modest revenue increases in the next fiscal year.
  • Low liquidity and dilution risk scores indicate a well-managed financial profile.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$225.42B
Gross profit$117.16B
Operating income$19.82B
Net income$14.10B
R&D
SG&A
D&A
SBC
Operating cash flow$15.29B
CapEx-$8.71B
Free cash flow$4.48B
Total assets$258.28B
Total liabilities$78.72B
Total equity$179.55B
Cash & equivalents$28.43B
Long-term debt$26.08B
Valuation
Market price$1431.00
Market cap$228.92B
Enterprise value$226.57B
P/E16.2
Reported non-GAAP P/E
EV/Revenue1.0
EV/Op income11.4
EV/OCF14.8
P/B1.3
P/Tangible book1.3
Tangible book$179.55B
Net cash$2.35B
Current ratio2.5
Debt/Equity0.1
ROA5.5%
ROE7.8%
Cash conversion1.1%
CapEx/Revenue-3.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
Metric6849Activity
Op margin8.8%-19.9% medp25 -150.5% · p75 8.7%top quartile
Net margin6.3%-18.4% medp25 -146.8% · p75 8.0%above median
Gross margin52.0%49.9% medp25 36.2% · p75 66.3%above median
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-3.9%-3.5% medp25 -7.8% · p75 -1.4%below median
Debt / equity15.0%14.5% medp25 0.9% · p75 54.2%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 18:01 UTC#c12c7bd7
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:21 UTCJob: 242e01fb